Get started
Author

Nathan Poterszman

Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
2024 · Eric Ouvrard, Ashjan Kaseb, et al. · Frontiers in Medicine · 31
PDF
Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors
2024 · Darejan Mamulashvili Bessac, Philippe Baltzinger, et al. · Endocrine · 8
Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma
2023 · Alessio Imperiale, Miriam Pepponi, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 7
A Hangover Under 177Lu-PSMA-617 Therapy: A Red Flag for Brain 68Ga-PSMA-11 PET/MRI?
2024 · Nathan Poterszman, Laura Somme, et al. · Clinical Nuclear Medicine · 4
Neuroendocrine peritoneal disease and [177Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications
2025 · Nathan Poterszman, Philippe Baltzinger, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 3
Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu‑PSMA‑617 therapy in metastatic castration-resistant prostate cancer
2025 · Nathan Poterszman, Cécile Hammer-Lefevre, et al. · Theranostics · 3
A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
2024 · Nathan Poterszman, Charles Merlin, et al. · Scientific Reports · 3
Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation
2026 · Olivia Lienhardt, Oreste Allegrini, et al. · EJNMMI Physics
[177Lu]Lu-PSMA extravasation: from quantitative imaging to clinical guidelines
2026 · Julien Salvadori, Oreste Allegrini, et al. · Physics in Medicine and Biology
Atteinte péritonéale des tumeurs neuro-endocrines de l’intestin grêle et traitement par 177Lu-DOTATATE : challenge thérapeutique et complications cliniques
2025 · N. Poterszman, P. Baltzinger, et al. · Médecine Nucléaire
Corrélation entre la positivité de la TEP TDM au 18F-PSMA-1008 et le groupe à risque d’une récidive biologique d’un cancer de la prostate selon l’EAU
2024 · N. Poterszman, C. Merlin, et al. · Médecine Nucléaire
Works count: 11
Citation count: 59
H-index: 4
I10-index: 1
Year
Topic
Type